GlassScriptPhysician profile
Christopher Todd Marazon
NPI 1700803699
$2,201.35
in general payments reported to CMS, 2019-2025
27 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $99.03 · 2021: $279 · 2022: $469 · 2023: $300 · 2024: $371 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $965.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $488.12 | 2022-2025 | |
| Amgen INC. | $380.10 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $198.56 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $184.91 | 2019-2025 | |
| Novo Nordisk INC | $174.88 | 2019-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $99.26 | 2021-2025 | Breztri, Airsupra |
| Abbott Laboratories | $76.59 | 2021-2024 | Freestyle Libre 3 |
| Allergan, INC. | $56.39 | 2019 | |
| Smith+Nephew, INC. | $54.73 | 2019 | |
| Sanofi Pasteur INC. | $52.84 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.01 | 2020-2025 | Xifaxan |
| Paratek Pharmaceuticals, INC. | $51.34 | 2025 | Nuzyra |
| Phathom Pharmaceuticals, INC. | $49.53 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $44.50 | 2021-2023 | Xarelto |
| Exact Sciences Corporation | $29.73 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $25.61 | 2021 | |
| Inspire Medical Systems, INC. | $23.52 | 2024 | Inspire |
| Kerecis Limited | $22.43 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Melinta Therapeutics, LLC | $22.42 | 2019 | |
| Apria Healthcare LLC | $17.32 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.65 | 2024 | Lifevest |
| Dexcom, INC. | $15.82 | 2021 | |
| Organon LLC | $13.77 | 2023 | Nexplanon |
| Bsn Medical INC | $13.75 | 2024 | |
| Lilly USA, LLC | $13.30 | 2023 | Jardiance, Emgality |
| Regeneron Healthcare Solutions, INC. | $12.05 | 2019 | |
| Amarin Pharma, INC. | $11.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Marazon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.